Tag: Athersys
Athersys announces ‘disappointing’ results from MASTERS-2 interim analysis
Athersys has announced that the independent data safety monitoring board (DSMB) has completed a preplanned interim analysis of the company’s ongoing, phase three MASTERS-2...
Athersys announces changes to MASTERS-2 trial endpoints following US FDA meeting
Athersys has announced planned amendments to its MASTERS-2 clinical trial protocol following a Type B meeting with the US Food and Drug Administration (FDA)....
Athersys granted clinical Type B meeting with US FDA to discuss...
Athersys, the company developing MultiStem (invimestrocel) cell therapy for critical care indications, announced recently that it has been granted a clinical Type B meeting with...
Athersys provides update on ischaemic stroke and haemorrhagic trauma trials of...
Athersys, the company developing MultiStem (invimestrocel)—an off-the-shelf stem cell treatment intended for critical care indications, including acute ischaemic stroke, trauma and other inflammatory conditions—has provided...
